studies are less likely to be published as compared to large studies. 9 It has also been shown that negative studies take longer to appear in print. 9 Another problem is one of covert duplicate publication, where the same study data is published more than once. 9 We found evidence of both publication bias and covert duplicate publication in our original meta-analysis.
It has also been documented that papers that appear in languages other than English are more likely to be excluded from metaanalyses. 9 All these biases are important and can invalidate the results of meta-analyses and, unfortunately, formal tests of publication bias are relatively weak tests.
Meta-analyses are therefore by no means perfect, for the reasons described above. Very large, well-designed primary studies remain the most reliable way of obtaining reproducible results. One of the reasons for the recent scepticism regarding the value of metaanalyses is the discrepancy between the results of meta-analyses and subsequent large studies, particularly in the context of clinical trials. For instance, in a meta-analysis, 15 it was shown that magnesium given intravenously for acute myocardial infarction decreases mortality in hospital, but a subsequent large scale trial, ISIS-4 16 in 1995, did not show any such effect. Similarly, aspirin was shown to prevent pre-eclampsia in a meta-analysis, 17 but a subsequent large-scale trial, CLASP 18 in 1994, did not show such a protective effect. Several authors have attempted to quantify the discrepancies between meta-analyses and subsequent large studies, and have found that approximately 80% directionally agreed with the result from larger trials. 19 More recently, a comparison of 12 randomised controlled trials with 19 previous meta-analyses 20 found that the results of the metaanalyses would have led to the adoption of an ineffective treatment in 32% of cases, and the rejection of a useful treatment in 33%.There have been attempts to explain these discrepancies using various models. 10, 11, 21 Given the complexities associated with meta-analysis, the data contributed and methodology applied should be both transparent and standard, so that they are not only reproducible, but can be reviewed with a critical eye. Recommendations regarding the minimum information that should be reported in a metaanalysis have been made. 8 What is of central importance is to appreciate that the conclusions of a meta-analysis are by no means definitive, and the apparent authority that these methods lend to consequent results is potentially dangerous. There are well-known cases of the conclusions of apparently adequate and comprehensive meta-analyses being subsequently shown to be false following the completion of large, definitive studies. The findings of Sen et al, 1 Schinka, 2 and Munafò et al, 3 indicate there is a degree of uncertainty regarding the effect of 5-HTT LPR genotype on anxiety-related traits using the scoring systems considered, and that measurement instrument may moderate this association. A large study with sufficient power and employing multiple phenotype measures would be a definitive means of resolving this complex and intriguing issue.
Tumour necrosis factor a polymorphism (À1031T/C) is associated with age of onset of schizophrenia SIR-Tumour necrosis factor alpha (TNF-a) is an important cytokine that plays a key role in inflammation and immunity. It is produced in the central nervous system where it participates in nerve-cell growth, differentiation and mediates synaptic integrity.
1 TNF-a is increased in serum in schizophrenic patients and correlates with total BPRS and Scale Assessment of Positive Symptoms scores in schizophrenia. 2 TNF-a may modulate the prodromal, acute, and residual phases of schizophrenia as well as influence response to treatment.
2 Increased TNF-a release in patients is normalized with antipsychotic treatment. 3 Thus, aberrant TNF-a may play a role in the pathogenesis and/or psychopathological symptoms in schizophrenia.
Studies have shown an association between the ÀG308A TNF-a polymorphism and schizophrenia, 4, 5 although other studies do not replicate the result. 6 The TNF-a gene is located right within the class III region of the major histocompatibility complex (MHC) on chromosome 6p21.3, a region associated with genetic susceptibility to schizophrenia. 7 Wilson et al 8 reported that a polymorphism (A-G) at position À308 in the promoter region of the TNF-a gene is associated with increased rate of transcription. This evidence has led to the hypothesis that a genetically determined increase in TNF-a production could increase susceptibility to developing schizophrenia. 4 Therefore, we investigated whether a T/C polymorphism at position À1031 in the promoter region of the TNF-a was associated with onset of schizophrenia.
A total of 111 inpatients (69 men and 42 women) meeting the DSM-IV criteria for schizophrenia and unrelated 146 healthy controls (94 men and 52 women) were included in the study. All patients were chronically ill (mean duration of illness 21.279.9 years). Normal controls were recruited from the local community, and matched for age and gender. All subjects were Han Chinese and came from the Beijing area and gave signed informed consent to participate. The study was approved by Peking University's Institutional Review Board, Institute of Mental Health. Blood samples were drawn and genomic DNA extracted. The À1031T/C polymorphism was genotyped using the method described previously 9 and was carried out blind to the clinical status.
Genotype frequency distributions, genotype, and allelic frequencies did not differ between patients and controls. No interaction was found between sex and genotypes. Table 1 shows the relationships between TNF-a genotype and clinical variables in schizophrenia patients. Age of onset significantly differed between the genotype groups (P ¼ 0.012). Age of onset was defined as the age at which the psychotic symptoms first appeared, according to medical case notes and interviews. Multiple regression revealed that the number of À1031C alleles (0,1,2) was parametrically related to age of onset after adding age and gender to the regression analysis (r 2 ¼ 0.06, P ¼ 0.017). TNF-a genotype accounted for 6% of the variance. To further confirm this relationship we expanded the number of patients to 230. An association between the -1031T/C genotypes and age of onset increased in significance (T/T, 24.176.0 years, n ¼ 151; T/C, 25.878.1 years, n ¼ 57; C/C, 30.5710.5 years, n ¼ 22) (F ¼ 7.61, df ¼ 2, 227, P ¼ 0.001).
Our results demonstrate that the -1031T/C polymorphism of the TNF-a gene is associated with age of onset of schizophrenia and provides further support for a relationship between this disease and aberrant TNF-a gene structure. This is consistent with other studies showing that TNF-a polymorphisms are associated with some aspect of schizophrenia. 4, 5 A direct effect of the TNF-a À1031T/C polymorphism itself may have contributed toward the present findings. Polymorphisms in the promoter region of the TNF-a gene affect TNF-a gene expression and protein production. 10 Abnormal levels of TNF-a at critical times in development may render individuals susceptible to schizophrenia. 4, 5 Other polymorphisms (À308G/A) are associated with elevated serum concentrations of TNF-a 8 and schizophrenia but not bipolar disorder. 5 These effects may also be due to linkage disequilibrium between this polymorphism and a functional polymorphism in or near the TNF-a gene. The TNF-a gene is located within the MHC, which is gene-dense and a highly polymorphic region, with the TNF-a gene itself containing a large number of polymorphisms. 10 Moreover, the MHC region is known to exhibit extensive linkage disequilibrium across the whole region.
In summary, although the mechanisms by which the À1031T/C genotype exerts its effects are still obscure, our results demonstrated for the first time that age of onset was associated with the TNF-a À1031T/C polymorphism. These results add to other findings showing aberrant TNF-a is associated with various aspects of schizophrenia. 
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